News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Novartis AG (NVS) Sees Boost From Program Designed to Speed Life-Saving Therapies


5/6/2013 8:13:52 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

Just as Novartis AG (NOVN)’s best-selling medicines are losing patent protection, the company is poised to get a revenue boost from a U.S. program designed to speed life- saving therapies to patients with few treatment options. Novartis, Europe’s biggest drugmaker, plans to seek approval to sell a new lung-cancer treatment as soon as next year after winning a “breakthrough” designation from the U.S. Food and Drug Administration. The breakthrough program is a response to demands from doctors and patients for quicker access to medicines under development. Earlier entry to the $5.8 billion lung-cancer market would help Novartis, based in Basel, Switzerland, fill a growing revenue gap as best-selling products Diovan for hypertension and Gleevec for cancer face competition from generic copies. The heart drug started to lose patent protection last year; Gleevec will be open to copies starting in 2015. Together, they generated $9.1 billion in sales last year.

Help employers find you! Check out all the jobs and post your resume.

Read at Bloomberg

comments powered by Disqus
Bloomberg
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES